# EDGAR Filing Document

**Accession Number:** 0001859007
**File Stem:** 0001493152-23-005155
**Filing Date:** 2023-2
**Character Count:** 1744
**Document Hash:** fc16534c898392ca66ec88ae3a20fb99
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-005155.hdr.sgml**: 20230524

**ACCESSION NUMBER**: 0001493152-23-005155

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZyVersa Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001859007
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 862685744
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876
- **BUSINESS PHONE:** 908-370-5102

**MAIL ADDRESS:**
- **STREET 1:** 217 W. MAIN STREET
- **CITY:** SOMERVILLE
- **STATE:** NJ
- **ZIP:** 08876

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Larkspur Health Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210426

February 15, 2023

*VIA EDGAR* 

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Lauren Hamill Laura Crotty

---

| | |
|:---|:---|
| **Re:** | **ZyVersa Therapeutics, Inc.** |
|  | **Registration Statement on Form S-1, as amended** |
|  | **File No. 333-269442** |

---

Ladies and Gentlemen:

ZyVersa Therapeutics, Inc. hereby requests that its acceleration request dated February 13, 2023 be withdrawn. Please call Jared Kelly of Lowenstein Sandler LLP at (973) 597-2400 with any questions.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| ZYVERSA THERAPEUTICS INC. | ZYVERSA THERAPEUTICS INC. |
| By: | */s/ Stephen Glover* |
| Name: | Stephen Glover |
| Title: | Chief Executive Officer |

---